The role of decision analysis in transfusion medicine

Vox Sanguinis

Volumn 71, Issue 1, 1996, Pages 1-5

  AuBuchon, James P ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD TRANSFUSION; DECISION THEORY; MEDICAL DECISION MAKING; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0029885975     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1423-0410.1996.7110001.x     Document Type: Short Survey

References (21)

1. Busch MP, Korelitz JJ, Kleinman SH, Lee SR, AuBuchon JP, Schreiber GB, and the Retrovirus Epidemiology in Donors Study (REDS): Declining yield of alanine aminotransferase testing for screening of blood donors for prevention of post-transfusion hepatitis B and C virus infection. Transfusion, in press.
2. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ: Incidence rates of infectious disease markers among volunteer blood donors: Estimating residual risk to the blood supply and projecting yields of additional screening tests. N Engl J Med, submitted.
3. Gmur J, Burger J, Schanz U, Fehr J, Schaffner A: Safety of stringent prophylactic platelet transfusion policy for patients with acute leuke-mia. Lancet 1991;338:1223-1226.
4. Mintz PD: Undertransfusion. Am J Clin Pathol 1992;98:150-151.
5. Berte LM: A quality system for transfusion medicine . . . and beyond. Med Lab Observer 1995;27:61-64.
6. Phelps CE: The methodologic foundations of studies of the appropriateness of medical care. NEJM 1993;329:1241-1245.
7. Phelps CE, Mushlin AI: Focusing technology assessment using medical decision theory. Med Decision Making 1988;8:279-289.
8. Phelps CE, Mooney C: Correction and update on 'priority setting in medical technology assessment'. Med Care 1992;30:744-751.
9. Wilson R, Crouch EAC. Risk assessment and comparisons: An introduction. Science 1987; 236:267-270.
10. Lave LB: Health and safety risk analyses: Information for better decisions. Science 1987; 236;291-295.
11. Eisenberg JM: Clinical economics. A guide to the economic analysis of clinical practices. JAMA 1989;262:2879-2886.
12. Weinstein MC, Stason WB: Foundation of cost-effectiveness analysis for health and medical practices. NEJM 1977;276:716-721.
13. AuBuchon JP, Birkmeyer JD, Busch MP: Cost-effectiveness of expanded HlV test protocols for donated blood (abstract). Transfusion 1995; 35:43S.
14. Check W: Red Cross considers adding HIV p24 antigen testing. CAP Today 1995;9:12.
15. American Association of Blood Banks; Bethesda: Association Bull No. 95-2, February 10, 1995.
16. Center for Biologics Evaluation and Research. Recommendations for donor screening with a licensed test for HIV-1 antigen. Rockville, Food and Drug Administration, August 8, 1995.
17. Birkmeyer JD, AuBuchon JP, Littenberg B, O'Connor GT, Nease RF, Nugent WC, Goodnoungh LT: The cost-effectiveness of preoperative autologous donation in coronary bypass surgery. Ann Thorac Surg 1994;57:161-169.
18. Weinstein MC, Stason WB: Cost-effectiveness of coronary artery bypass surgery. Circulation 1982;66(suppl 3):56-66.
19. Evans RW: Cost-effectiveness analysis of transplantation. Surg Clin North Am 1986;66:603-616.
20. Stange PV, Sumner AT: Predicting treatment costs and life expectancy for end-stage renal disease. N Engl J Med 1978;298:372-378.
21. Birkmeyer JD, Goodnough LT, AuBuchon JP, Noordsij PG, Littenberg B: The cost-effectiveness of preoperative autologous blood donation in total hip and knee replacement. Transfusion 1993;33:544-551.